<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01090362</url>
  </required_header>
  <id_info>
    <org_study_id>TRI08888</org_study_id>
    <nct_id>NCT01090362</nct_id>
  </id_info>
  <brief_title>Global Anticoagulant Registry in the Field</brief_title>
  <acronym>GARFIELD-AF</acronym>
  <official_title>Prospective, Multi Centre, International Registry of Male and Female Patients Newly Diagnosed With Atrial Fibrillation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thrombosis Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Advanced Drug and Device Services SAS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apothecaries Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thrombosis Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF Registry) is&#xD;
      a non-interventional, observational study that characterized a global population of&#xD;
      non-valvular atrial fibrillation patients. The registry was used to document global baseline&#xD;
      characteristics, current treatment strategies and outcome measures. Characterisation of a&#xD;
      number of AF sub-populations was also completed. GARFIELD-AF is an independent academic&#xD;
      research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported&#xD;
      by an unrestricted research grant from Bayer AG (Berlin, Germany).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using data from more than 1000 randomly selected centres across 35 countries, representing&#xD;
      all possible care settings, the registry will help to characterize real-life anticoagulant&#xD;
      treatment patterns and outcomes, including rates of stroke and bleeding complications, as&#xD;
      well as provide data on other important issues, such as physicians' compliance with&#xD;
      guidelines and patients' adherence to therapy. This is particularly timely as standard&#xD;
      practice moves away from vitamin K antagonist (VKA)-dominated therapy and towards a new era&#xD;
      of novel oral anticoagulants (OACs), i.e. direct Factor Xa inhibitors and direct thrombin&#xD;
      inhibitors.&#xD;
&#xD;
      To ensure a dataset that truly reflects current practice, the investigators are requested to&#xD;
      prospectively enrol all newly diagnosed patients with non-valvular AF who have at least one&#xD;
      additional investigator-determined risk factor for stroke. Patients are consecutively&#xD;
      recruited into one of five cohorts and followed up for at least 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2009</start_date>
  <completion_date type="Actual">May 18, 2020</completion_date>
  <primary_completion_date type="Actual">June 16, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>4 months</time_frame>
    <description>All cause mortality including cardiovascular and non-cardiovascular death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>8 months</time_frame>
    <description>All cause mortality including cardiovascular and non-cardiovascular death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>12 months</time_frame>
    <description>All cause mortality including cardiovascular and non-cardiovascular death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>16 months</time_frame>
    <description>All cause mortality including cardiovascular and non-cardiovascular death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>20 months</time_frame>
    <description>All cause mortality including cardiovascular and non-cardiovascular death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>24 months</time_frame>
    <description>All cause mortality including cardiovascular and non-cardiovascular death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>3 years</time_frame>
    <description>All cause mortality including cardiovascular and non-cardiovascular death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>4 years</time_frame>
    <description>All cause mortality including cardiovascular and non-cardiovascular death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke/Systemic embolism (SE)</measure>
    <time_frame>4 months</time_frame>
    <description>Stroke/SE was defined as the combined end points of ischemic stroke, and SE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke/Systemic embolism (SE)</measure>
    <time_frame>8 months</time_frame>
    <description>Stroke/SE was defined as the combined end points of ischemic stroke, and SE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke/Systemic embolism (SE)</measure>
    <time_frame>12 months</time_frame>
    <description>Stroke/SE was defined as the combined end points of ischemic stroke, and SE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke/Systemic embolism (SE)</measure>
    <time_frame>16 months</time_frame>
    <description>Stroke/SE was defined as the combined end points of ischemic stroke, and SE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke/Systemic embolism (SE)</measure>
    <time_frame>20 months</time_frame>
    <description>Stroke/SE was defined as the combined end points of ischemic stroke, and SE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke/Systemic embolism (SE)</measure>
    <time_frame>24 months</time_frame>
    <description>Stroke/SE was defined as the combined end points of ischemic stroke, and SE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke/Systemic embolism (SE)</measure>
    <time_frame>3 years</time_frame>
    <description>Stroke/SE was defined as the combined end points of ischemic stroke, and SE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke/Systemic embolism (SE)</measure>
    <time_frame>4 years</time_frame>
    <description>Stroke/SE was defined as the combined end points of ischemic stroke, and SE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>4 months</time_frame>
    <description>Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>8 months</time_frame>
    <description>Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>16 months</time_frame>
    <description>Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>20 months</time_frame>
    <description>Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>4 years</time_frame>
    <description>Defined as clinically overt bleeding associated with a critical site or hemorrhagic stroke, a fall in haemoglobin of ≥2 g/dl, transfusion of ≥2 units of packed red blood cells, or fatal outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular events defined as Stroke</measure>
    <time_frame>4 months</time_frame>
    <description>Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular events defined as Stroke</measure>
    <time_frame>8 months</time_frame>
    <description>Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular events defined as Stroke</measure>
    <time_frame>12 months</time_frame>
    <description>Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular events defined as Stroke</measure>
    <time_frame>16 months</time_frame>
    <description>Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular events defined as Stroke</measure>
    <time_frame>20 months</time_frame>
    <description>Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular events defined as Stroke</measure>
    <time_frame>24 months</time_frame>
    <description>Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular events defined as Stroke</measure>
    <time_frame>3 years</time_frame>
    <description>Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrovascular events defined as Stroke</measure>
    <time_frame>4 years</time_frame>
    <description>Primary ischaemic stroke, Primary intracerebral haemorrhage, Secondary haemorrhagic ischaemic stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Ischemic Attacks (TIA)</measure>
    <time_frame>4 months</time_frame>
    <description>Number of Transient Ischemic Attacks (TIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Ischemic Attacks (TIA)</measure>
    <time_frame>8 months</time_frame>
    <description>Number of Transient Ischemic Attacks (TIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Ischemic Attacks (TIA)</measure>
    <time_frame>12 months</time_frame>
    <description>Number of Transient Ischemic Attacks (TIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Ischemic Attacks (TIA)</measure>
    <time_frame>16 months</time_frame>
    <description>Number of Transient Ischemic Attacks (TIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Ischemic Attacks (TIA)</measure>
    <time_frame>20 months</time_frame>
    <description>Number of Transient Ischemic Attacks (TIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Ischemic Attacks (TIA)</measure>
    <time_frame>24 months</time_frame>
    <description>Number of Transient Ischemic Attacks (TIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Ischemic Attacks (TIA)</measure>
    <time_frame>3 years</time_frame>
    <description>Number of Transient Ischemic Attacks (TIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Ischemic Attacks (TIA)</measure>
    <time_frame>4 years</time_frame>
    <description>Number of Transient Ischemic Attacks (TIA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute coronary syndromes</measure>
    <time_frame>4 months</time_frame>
    <description>Number including unstable angina, STEMI, Non-STEMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute coronary syndromes</measure>
    <time_frame>8 months</time_frame>
    <description>Number including unstable angina, STEMI, Non-STEMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute coronary syndromes</measure>
    <time_frame>12 months</time_frame>
    <description>Number Including unstable angina, STEMI, Non-STEMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute coronary syndromes</measure>
    <time_frame>16 months</time_frame>
    <description>Number including unstable angina, STEMI, Non-STEMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute coronary syndromes</measure>
    <time_frame>20 months</time_frame>
    <description>Number including unstable angina, STEMI, Non-STEMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute coronary syndromes</measure>
    <time_frame>24 months</time_frame>
    <description>Number including Unstable angina, STEMI, Non-STEMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute coronary syndromes</measure>
    <time_frame>3 years</time_frame>
    <description>Number including unstable angina, STEMI, Non-STEMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute coronary syndromes</measure>
    <time_frame>4 years</time_frame>
    <description>Number including unstable angina, STEMI, Non-STEMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy persistence</measure>
    <time_frame>4 months</time_frame>
    <description>Participant duration of time on therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy persistence</measure>
    <time_frame>8 months</time_frame>
    <description>Participant duration of time on therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy persistence</measure>
    <time_frame>12 months</time_frame>
    <description>Participant duration of time on therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy persistence</measure>
    <time_frame>16 months</time_frame>
    <description>Participant duration of time on therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy persistence</measure>
    <time_frame>20 months</time_frame>
    <description>Participant duration of time on therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy persistence</measure>
    <time_frame>24 months</time_frame>
    <description>Participant duration of time on therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy persistence</measure>
    <time_frame>3 years</time_frame>
    <description>Participant rate of discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy persistence</measure>
    <time_frame>4 years</time_frame>
    <description>Participant duration of time on therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of other clinical events</measure>
    <time_frame>4 months</time_frame>
    <description>Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of other clinical events</measure>
    <time_frame>8 months</time_frame>
    <description>Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of other clinical events</measure>
    <time_frame>12 months</time_frame>
    <description>Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of other clinical events</measure>
    <time_frame>16 months</time_frame>
    <description>Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of other clinical events</measure>
    <time_frame>20 months</time_frame>
    <description>Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of other clinical events</measure>
    <time_frame>24 months</time_frame>
    <description>Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of other clinical events</measure>
    <time_frame>3 years</time_frame>
    <description>Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of other clinical events</measure>
    <time_frame>4 years</time_frame>
    <description>Myocardial infarction (MI)/ acute coronary syndromes (ACS), and congestive heart failure (CHF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>4 months</time_frame>
    <description>Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>8 months</time_frame>
    <description>Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>12 months</time_frame>
    <description>Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>16 months</time_frame>
    <description>Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>20 months</time_frame>
    <description>Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>24 months</time_frame>
    <description>Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>3 years</time_frame>
    <description>Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>4 years</time_frame>
    <description>Frequency, severity, location, outcome, Healthcare utilisation used for bleeding event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Embolism</measure>
    <time_frame>4 months</time_frame>
    <description>Number of participants with a Pulmonary Embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Embolism</measure>
    <time_frame>8 months</time_frame>
    <description>Number of participants with a Pulmonary Embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Embolism</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with a Pulmonary Embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Embolism</measure>
    <time_frame>16 months</time_frame>
    <description>Number of participants with a Pulmonary Embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Embolism</measure>
    <time_frame>20 months</time_frame>
    <description>Number of participants with a Pulmonary Embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Embolism</measure>
    <time_frame>24 months</time_frame>
    <description>Number of participants with a Pulmonary Embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Embolism</measure>
    <time_frame>3 years</time_frame>
    <description>Number of participants with a Pulmonary Embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Embolism</measure>
    <time_frame>4 years</time_frame>
    <description>Number of participants with a Pulmonary Embolism</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Actual">57250</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Cohort complete with 5,088 retrospective patients and 5,499 prospective patients recruited from 19 countries.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Cohort completed with 11,351 patients enrolled from 30 countries</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <description>Cohort 3 completed with 11,139 patients enrolled globally from 32 countries</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <description>Cohort 4 completed with 11,2780 patients enrolled from 35 countries.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <description>Final cohort completed with 12,186 patients enrolled.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female patients newly diagnosed with atrial fibrillation (AF) who are with at&#xD;
        least one additional risk of stroke from 18 countries globally.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Prospective Cohort&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  New diagnosis of non-valvular atrial fibrillation (diagnosed within the last 6 weeks)&#xD;
             with at least one additional risk factor for stroke and regardless of therapy.&#xD;
&#xD;
        Retrospective validation cohort&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  Diagnosis of non-valvular AF (diagnosed 6-24 months prior to enrolment) with at least&#xD;
             one additional risk factor for stroke and regardless of therapy.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  No further follow-up envisaged or possible within enrolling hospital or with&#xD;
             associated family practitioner.&#xD;
&#xD;
          -  Patients with transient AF secondary to a reversible cause.&#xD;
&#xD;
          -  Patients recruited in controlled clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajay K Kakkar</last_name>
    <role>Study Director</role>
    <affiliation>Thrombosis Research Institute, London, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prof. Samuel Goldhaber</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Hector Luciardi, National Co-ordinating Investigator, National University of Tucuman</name>
      <address>
        <city>Tucumán</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harry Gibbs, National Co-ordinating Investigator, The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marianne Brodmann: National Co-ordinating Investigator, Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Frank Cools, National Co-ordinating Investigator, AZ Klina</name>
      <address>
        <city>Brasschaat</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Antonio Barretto, National Coordinating Investigator, Hospital Santa Marcelina,</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof Stuart Connolly and Dr John Eikelboom, National Coodinating Investigators, Mc Master University</name>
      <address>
        <city>Hamilton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Ramon Corbalan, National Coordinating Investigator, Pontifica Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof Zin-Cheng, National Coordinating Investigator, Peking Union Medical College &amp; Chinese Academy Medical Sciences People Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Petr Jansky, National Coordinating Investigator, Cardiovaskular Center, Motol Univesity Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof Joern Dalsgaard Nielsen, National Coordinating Investigator, Bispebjerg &amp; Frederiksberg Hospitals</name>
      <address>
        <city>Frederiksberg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Hany Ragy, National Coordinating Investigator, Hayat Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof Pekka Raatikainen, National Coordinating Investigator, Univesrsity of Tampere</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Jean-Yues LeHeuzey, National Coordinating Investigator, Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof Harald Darius, National oordinating Investigator, Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Matyas Keltai, National Coordinating Investigator, Hungarian Institute of Cardiology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Sawney, National Coordinating Investigator, Sir Ganga Ram Hospital, New Delhi</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profs Giancarlo Agnelli and Giuseppe Ambrosio, National Coordinating Investigators, University of Perugia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professor Yukihiro Koretsune, National Coordinating Investigator, Osaka National Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Seil Oh, National Coordinating Investigator, National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Carlos Jerjes Sanchez Diaz, National Coordinating Investigator,Tecnologico de Monterrey</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professor Hugo ten Cate, National Coordinating Investigator, Cardiovascular Research Institute Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professor Dan Atar, National Coordinating Investigator, Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof Janina Stępińska, National Coordinating Investigator, Institute of Cardiology, Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professor Elizaveta Panchenko, National Coordinating Investigator, Cardiology Research and Production Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Toon Wei Lim, National Coordinating Investigator, National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Barry Jacobson, National Coordinating Investigator, University of the Witwatersrand</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Xavier Vinolas, National Coordinating Investigator, Hospital Santa Creu y San Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Marten Rosenqvist, National Coordinating Investigator, Karolinska Institute</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Jan Steffel, National Coordinating Investigator, University Hospital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Pantep Angchaisuksiri, National Coordinating Investigator, Ramathibodi Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professor Ali Oto, National Coordinating Investigator, Memorial Ankara Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Alexandr Parkhomenko, National Coordinating Investigator, Strazhesko Institute of Cardiology</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Wael Al Mahmeed, National Coordinating Investigator, SKMC Cardiac Siences</name>
      <address>
        <city>Abu Dhabi</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. David Fitzmaurice, National Coordinating Investigator, University of Warwick</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Egypt</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Arab Emirates</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.tri-london.ac.uk/garfield</url>
    <description>Sponsor's website</description>
  </link>
  <reference>
    <citation>Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Verheugt FW, Jamal W, Misselwitz F, Rushton-Smith S, Turpie AG. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J. 2012 Jan;163(1):13-19.e1. doi: 10.1016/j.ahj.2011.09.011. Epub 2011 Nov 20.</citation>
    <PMID>22172431</PMID>
  </reference>
  <reference>
    <citation>Apenteng PN, Murray ET, Holder R, Hobbs FD, Fitzmaurice DA; UK GARFIELD Investigators and GARFIELD Steering Committee. An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. BMC Cardiovasc Disord. 2013 Apr 23;13:31. doi: 10.1186/1471-2261-13-31.</citation>
    <PMID>23617744</PMID>
  </reference>
  <reference>
    <citation>Aalbers J. GARFIELD: a window on the real-life treatment of atrial fibrillation - South Africa joins the GARFIELD registry. Cardiovasc J Afr. 2012 Oct;23(9):528.</citation>
    <PMID>23108524</PMID>
  </reference>
  <results_reference>
    <citation>Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY, Mantovani LG, Turpie AG, van Eickels M, Misselwitz F, Rushton-Smith S, Kayani G, Wilkinson P, Verheugt FW; GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013 May 21;8(5):e63479. doi: 10.1371/journal.pone.0063479. Print 2013.</citation>
    <PMID>23704912</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 18, 2010</study_first_submitted>
  <study_first_submitted_qc>March 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2010</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Stroke</keyword>
  <keyword>Stroke prevention</keyword>
  <keyword>Health Economics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

